Abstract:The aim of the present study was to investigate the clinical, pathological and prognostic characteristics of Chinese patients with resected pancreatic neuroendocrine neoplasms (p-NENs). Data from patients who were surgically treated and pathologically diagnosed with p-NENs at the Department of Pancreatic Oncology of the Fudan University Shanghai Cancer Center (Shanghai, China), between January 2003 and July 2015, were evaluated using univariate and multivariate analyses. A total of 162 patients with p-NENs met the criteria of the present study and were included in the analysis. Patients with poorly differentiated pancreatic neuroendocrine carcinoma (p-NEC) exhibited a significantly increased rate of lymph node metastasis, as compared with patients with grade (G)1/G2 pancreatic neuroendocrine tumors (p-NETs) (62.5 vs. 20.5%, P=0.003). Univariate analysis identified that the following factors led to decreased overall survival (OS): Lymph node metastasis (P=0.001, vs. the absence of lymph node metastasis); distant metastasis (P=0.043, vs. the absence of distant metastasis); resection margin R1/R2 (P=0.030, vs. R0 resection); NEC G3 (P<0.001, vs. NET G1). Following the multivariate analysis, NEC G3 remained a statistically significant risk factor (HR=12.593; 95% CI, 3.476-45.622; P<0.001, vs. NET G1/G2). Furthermore, according to the proliferation marker protein Ki-67 staining index, assigning a grade using the proliferative index (G1, ≤5%; G2, >5-20%; G3, >20%) was more efficient for prognostic stratification compared with the European Neuroendocrine Tumor Society (Berlin, Germany)/World Health Organization (Geneva, Switzerland) 2010 grading classification. The present study indicated that p-NEC was an important predictor of decreased OS in Chinese patients. Furthermore, a Ki-67 staining index of 5% represented a more efficient value for the distinction between G1 and G2.

[The Chinese Guidelines for the Diagnosis and Treatment of Pancreatic Neuroendocrine Neoplasms (2020)].

Updated Understanding on the National Comprehensive Cancer Network Guidelines (version 1. 2017) for Diagnosis and Treatment of Pancreatic Adenocarcinoma

Guidelines for the Diagnosis and Treatment of Pancreatic Cancer in China (2021)

[Consensus and controversy of endoscopic diagnosis and treatment of gastroenteropancreatic neuroendocrine tumors]

Consensus on the Clinical Diagnosis and Treatment of Grade 3 Pancreatic Neuroendocrine Tumors

Consensus of Clinical Diagnosis and Treatment for Non-Functional Pancreatic Neuroendocrine Neoplasms with Diameter <2 Cm

Surgical management for non-functional pancreatic neuroendocrine neoplasms with synchronous liver metastasis: A consensus from the Chinese Study Group for Neuroendocrine Tumors (CSNET)

Chinese Society of Clinical Oncology (CSCO): Clinical guidelines for the diagnosis and treatment of pancreatic cancer

The Chinese Guidelines for Neoadjuvant Therapy of Pancreatic Cancer (2020)

[The Diagnosis and Treatment of Pancreatic Neuroendocrine Neoplasms].

2017 ENETS consensus guidelines: update for the standard of care of pancreatic neuroendocrine tumors

Chinese Expert Consensus on Multidisciplinary Diagnosis and Treatment of Pancreatic Neuroendocrine Liver Metastases

Clinical Outcomes and Prognostic Factors of Resected Pancreatic Neuroendocrine Neoplasms: A Single-Center Experience in China.

Reflections on hot issues of pancreatic neuroendocrine neoplasms

Updates on the research and management of pancreatic neuroendocrine neoplasm in 2021

Gastroenteropancreatic neuroendocrine neoplasms: current development, challenges, and clinical perspectives

Diagnosis and Surgical Treatment of Pancreatic Neuroendocrine Neoplasms

Surgery management for sporadic small (≤2 cm), non-functioning pancreatic neuroendocrine tumors: a consensus statement by the Chinese Study Group for Neuroendocrine Tumors (CSNET)

JNETS clinical practice guidelines for gastroenteropancreatic neuroendocrine neoplasms: diagnosis, treatment, and follow-up: a synopsis

Guidelines for the Diagnosis and Treatment of Hepatocellular Carcinoma (2019 Edition).

New insights in diagnosis and treatment of gastroenteropancreatic neuroendocrine neoplasms